What is Breaking?
Breaking is a pioneering company operating at the intersection of plastic degradation and synthetic biology. Its core technology, developed from a foundational discovery at the Wyss Institute for Biologically Inspired Engineering at Harvard University, aims to address the global plastic waste crisis through biological means. The company was gestated at Colossal Biosciences, leveraging advanced biotechnological platforms to engineer solutions for environmental remediation.
The company's focus on synthetic biology positions it to develop novel enzymes or microbial systems capable of breaking down persistent plastic materials, offering a sustainable alternative to traditional recycling and disposal methods. This strategic direction aligns with increasing global demand for eco-friendly solutions and circular economy principles.
How much funding has Breaking raised?
Breaking has raised a total of $10.5M across 1 funding round:
Angel/Seed
$10.5M
Angel/Seed (2024): $10.5M, investors not publicly disclosed
What's next for Breaking?
With the recent major strategic investment and a substantial total funding base of $10.5M, Breaking is poised for significant expansion and acceleration of its research and development initiatives. The enterprise-level funding suggests a focus on scaling operations, advancing its proprietary technology towards commercial viability, and potentially forging strategic partnerships within the chemical and materials industries.
The company's next phase will likely involve rigorous testing, pilot-scale deployments, and regulatory approvals, aiming to translate its scientific breakthroughs into impactful environmental solutions. Continued backing from investors signals a strong belief in Breaking's potential to disrupt the plastic waste management landscape.
